Oxidative Stress Levels, JAK2V617F Mutational Status and Thrombotic Complications in Patients with Essential Thrombocythemia

被引:0
|
作者
Moisa, Cornel [1 ]
Gaman, Mihnea Alexandru [2 ]
Diaconu, Camelia Cristina [2 ,3 ]
Gaman, Amelia Maria [4 ,5 ]
机构
[1] Cty Emergency Hosp Slatina, Dept Haematol, 5 Crisan Str, Slatina 230008, Romania
[2] Carol Davila Univ Med & Pharm, 8 Eroii Sanit Blvd, Bucharest 050474, Romania
[3] Clin Emergency Hosp Bucharest, Internal Med Clin, 8 Calea Floreasca Str, Bucharest 014461, Romania
[4] Univ Med & Pharm Craiova, Dept Pathophysiol, 2 Petru Rares Str, Craiova 200349, Romania
[5] Filantropia City Hosp, Clin Haematol, 1 Filantropiei Str, Craiova 200143, Romania
来源
REVISTA DE CHIMIE | 2019年 / 70卷 / 08期
关键词
essential thrombocythemia; reactive oxygen species; total antioxidant capacity; JAK2V617F; thrombosis; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; CALRETICULIN; ACTIVATION; PLATELET; INFLAMMATION; IMPACT; MPL;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Essential thrombocythemia (ET) is a BCR-ABL1-negative myeloproliferative neoplasm associated with thrombotic and haemorrhagic complications. Reactive oxygen species (ROS) overexpression induces a growth advantage to JAK2V617F-positive clones and, in association with a higher number of immature platelets, leukocytosis, and additional cardiovascular risk factors, leads to an increased risk for thrombotic events. We evaluated oxidative stress by measuring ROS levels and the total antioxidant capacity (TAC) in 62 ET patients and investigated the relationship between oxidative stress, JAK2V617F mutational status and the development of thrombotic events. We found higher oxidative stress levels in JAK2V617F-positive vs. JAK2V617F-negative ET cases with no significant differences between homozygous and heterozygous genotypes. Increased ROS levels and thrombotic events were more frequent in ET patients with old age at diagnosis, higher haematocrit levels or leukocytosis.
引用
收藏
页码:2822 / 2825
页数:4
相关论文
共 50 条
  • [31] The phenotype of JAK2V617F mutant patients with essential thrombocythemia is not related to the burden of mutant allele
    Antonioli, E.
    Guglielmelli, P.
    Poli, G.
    Longo, G.
    Ponziani, V.
    Pancrazzi, A.
    Bosi, A.
    Vannucchi, A. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 335 - 335
  • [32] Frequency of the JAK2V617F mutation in platelets from essential thrombocythemia (ET) patients.
    Heller, PG
    Lev, PR
    Salim, JP
    Kornblihtt, LI
    Vassallu, PS
    Goette, NP
    Chazarreta, DC
    Glembotsky, AC
    Marta, RF
    Molinas, FC
    BLOOD, 2005, 106 (11) : 324B - 324B
  • [33] The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status—clinical correlates in a study of 226 consecutive patients
    A Pardanani
    T L Lasho
    C M Finke
    N Gangat
    A P Wolanskyj
    C A Hanson
    A Tefferi
    Leukemia, 2010, 24 : 110 - 114
  • [34] Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy
    Jacek Treliński
    Krzysztof Chojnowski
    Barbara Cebula-Obrzut
    Piotr Smolewski
    Medical Oncology, 2012, 29 : 2388 - 2395
  • [35] THE JAK2V617F MUTATION STATUS AND ALLELE BURDEN IN THAI PATIENTS WITH POLYCYTHEMIA VERA (PV) AND ESSENTIAL THROMBOCYTHEMIA (ET)
    Singdong, Roongrudee
    Siriboonpiputtana, Teerapong
    Kongruang, Adcharee
    Limsuwanachot, Nittaya
    Chareonsirisuthigul, Takol
    Chuncharunee, Suporn
    Sirirat, Tanasan
    Rerkamnuaychoke, Budsaba
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 : 98 - 98
  • [36] JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events
    Alvarez-Larran, Alberto
    Bellosillo, Beatriz
    Pereira, Arturo
    Kerguelen, Ana
    Carlos Hernandez-Boluda, Juan
    Martinez-Aviles, Luz
    Fernandez-Rodriguez, Concepcion
    Gomez, Montse
    Lombardia, Luis
    Angona, Anna
    Ancochea, Agueda
    Senin, Alicia
    Longaron, Raquel
    Navarro, Blanca
    Collado, Maria
    Besses, Carlos
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (05) : 517 - 523
  • [37] NEUROLOGICAL SYMPTOMS IN ESSENTIAL THROMBOCYTHEMIA: IMPACT OF JAK2V617F MUTATION AND RESPONSE TO THERAPY
    Elli, E.
    Cecchetti, C.
    Brambilla, C.
    Belotti, A.
    Gandossini, L.
    Pogliani, E. M.
    HAEMATOLOGICA, 2012, 97 : 638 - 638
  • [38] The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients
    Pardanani, A.
    Lasho, T. L.
    Finke, C. M.
    Gangat, N.
    Wolanskyj, A. P.
    Hanson, C. A.
    Tefferi, A.
    LEUKEMIA, 2010, 24 (01) : 110 - 114
  • [39] RELATION BETWEEN JAK2V617F MUTATION AND MYELOPROLIFERATIVE AND ANGIOGENIC INDEX IN ESSENTIAL THROMBOCYTHEMIA
    Cacciola, E.
    Di Francesco, E.
    Pezzella, E.
    Tibullo, D.
    Cacciola, R. R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 510 - 510
  • [40] Neurological symptoms in essential thrombocythemia: impact of JAK2V617F mutation and response to therapy
    Aroldi, Andrea
    Cecchetti, Caterina
    Colombo, Arianna
    Cattaneo, Leonardo
    Pioltelli, Pietro Enrico
    Pogliani, Enrico Maria
    Elli, Elena Maria
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (06) : 593 - 601